Hypothalamic–pituitary–somatotropic axis with growth hormone deficiency or Laron syndrome ( insensitivity) show symptoms like short stature, dwarfism and obesity, but are also protected from some forms of cancer. Conversely, acromegaly and gigantism are conditions of GH and IGF-1 excess usually due to a pituitary tumor, and are characterized by overgrowth and tall stature. Hypothalamic–pituitary–somatotropic axis The hypothalamic–pituitary–somatotropic axis (HPS axis), or hypothalamic–pituitary–somatic axis, also known as the hypothalamic–pituitary–growth axis, is a hypothalamic–pituitary axis which includes the secretion of growth hormone (GH; somatotropin) from the somatotropes of the pituitary gland into the circulation and the subsequent stimulation of insulin-like growth factor 1 (IGF-1;
Pituitary adenoma only, with no other associated symptoms that occur in Multiple endocrine neoplasia Type 1 or Carney complex. FIPA was first described in a limited cohort of families by group in Liège, Belgium ; later FIPA was fully characterized in a multicenter international study of 64 families. FIPA families are divided into those that are homogenous and have the same type of pituitary adenoma in all the affected family members (e.g. only acromegaly, only prolactinoma, etc) , while heterogeneous FIPA families can have different pituitary adenomas in affected family members. FIPA has two known genetic causes, mutations in the "aryl hydrocarbon